BioVie Inc. (NASDAQ:BIVI) Short Interest Update

BioVie Inc. (NASDAQ:BIVI) was the recipient of a significant increase in short interest during the month of December. As of December 15th, there was short interest totalling 2,090,000 shares, an increase of 13.6% from the November 30th total of 1,840,000 shares. Based on an average daily trading volume, of 5,990,000 shares, the days-to-cover ratio is currently 0.3 days.

BioVie Price Performance

NASDAQ BIVI traded down $0.09 on Tuesday, hitting $2.00. 1,200,976 shares of the company’s stock were exchanged, compared to its average volume of 1,662,129. The firm’s 50-day moving average price is $2.71 and its two-hundred day moving average price is $1.96. The firm has a market cap of $35.54 million, a price-to-earnings ratio of -0.17 and a beta of 0.40. BioVie has a fifty-two week low of $1.04 and a fifty-two week high of $33.10.

BioVie (NASDAQ:BIVI) last released its quarterly earnings data on Monday, September 30th. The company reported ($6.60) EPS for the quarter.

About BioVie

BioVie Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease.